Court Blocks Israeli Co. From Suing Amgen
Notching a win for Amgen Inc. in a protracted patent dispute over its arthritis drug Enbrel, a U.S. federal appeals court has found that an Israeli company cannot collect royalties on...To view the full article, register now.
Already a subscriber? Click here to view full article